Derek Kennedy

Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.

S. Bunting, C. O’Neill, L. Tsuruda, 2011, Molecular genetics and metabolism.

Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)

C. O’Neill, M. Katz, J. Coates, 2014, Journal of neuroscience research.

Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.

K. Narfström, C. O’Neill, M. Katz, 2014, Experimental eye research.

Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.

J. Cooper, Joshua Henshaw, C. O’Neill, 2015, Molecular genetics and metabolism.

Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution.

C. O’Neill, L. Tsuruda, D. Musson, 2014, Toxicology and applied pharmacology.

Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease

Joshua Henshaw, C. O’Neill, M. Katz, 2021, Clinical and translational science.

Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease

C. O’Neill, L. Tsuruda, M. Butt, 2017, The Journal of Pharmacology and Experimental Therapeutics.